The $180 million capital raise provides Achieve Life Sciences with significant cash to fund operations but comes at a cost of substantial dilution and loss of governance control to the participating investors. Traders should monitor how the company deploys this capital and whether the new board members influence strategic direction. The registration rights granted to investors will allow them to sell their shares, potentially increasing stock volatility when the registration becomes effective.
Price Chart
Executive Summary
Achieve Life Sciences (ACHV) raised $180 million through a private placement of common stock, pre-funded warrants, and accompanying common warrants to investors. The company also appointed directors designated by key investors Frazier, TPG, and venBio, and disclosed the transaction publicly. This capital raise is dilutive and gives significant board influence to the participating investors.
Key Financial Metrics
Key Facts
- Achieve Life Sciences raised $180 million in an unregistered private placement.
- The offering included common stock, pre-funded warrants, and accompanying common warrants.
- The company appointed board members designated by investors Frazier, TPG, and venBio.
- The transaction is dilutive to existing shareholders and gives significant governance influence to the new investors.
- The company will file a registration statement to allow resale of the securities.
Financial Impact
The company raised $180 million in gross proceeds through the sale of common stock, pre-funded warrants, and common warrants. The offering is dilutive to existing shareholders.
Risk Factors
- Significant dilution to existing shareholders from the issuance of new shares and warrants.
- Loss of governance control as key investors gain board representation.
- Potential for increased stock volatility when registration becomes effective and investors can sell.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-159189 |
| Document: achv-ex4_1.htm | 0001193125-26-159189 |
| Document: achv-ex10_2.htm | 0001193125-26-159189 |
| Document: achv-ex4_2.htm | 0001193125-26-159189 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 20d ago | 3 | $7.24 $7.19 | ▼ −0.69% | ▼ −0.27% | $6.54 (−9.67%) |
Oct 1, 2026 25d ago | 8-K | $7.24 $7.01 | ▼ −3.18% | ▼ −3.85% | $6.54 (−9.67%) |
Aug 14, 2026 10w ago | 8-K | $7.50 $7.52 | ▼ −0.27% | ▼ −0.94% | $6.54 (+12.80%) |
Aug 11, 2026 10w ago | 8-K | $6.69 $7.25 | ▲ +8.37% | ▲ +7.67% | $6.54 (−2.24%) |
Aug 11, 2026 10w ago | Press Release | $6.77 $6.69 | ▲ +1.18% | ▲ +1.43% | $6.54 (+3.40%) |
Aug 7, 2026 11w ago | Institutional Cluster | $6.65 $6.67 | ▲ +0.30% | ▲ +0.33% | $6.54 (−1.65%) |
Jun 11, 2026 19w ago | Institutional Cluster | $5.52 $5.52 | · 0.00% | ▲ +0.54% | $6.54 (−18.48%) |
Jun 2, 2026 20w ago | 8-K | $5.03 $4.92 | ▼ −2.19% | ▼ −1.49% | $6.54 (+30.02%) |
May 22, 2026 22w ago | EFFECT | $4.69 $4.56 | ▲ +2.77% | ▲ +3.36% | $6.54 (−39.45%) |
May 19, 2026 22w ago | Press Release | $4.45 $4.57 | ▲ +2.70% | ▲ +1.66% | $6.54 (+46.97%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers